<DOC>
	<DOCNO>NCT00026533</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth thyroid cancer stop blood flow tumor . PURPOSE : Phase II trial study effectiveness thalidomide treat patient thyroid cancer .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity thalidomide , term tumor response duration response , patient metastatic follicular , papillary , medullary thyroid carcinoma unresponsive systemic radioiodine . - Compare difference antitumor activity drug patient medullary carcinoma vs papillary follicular carcinoma . - Determine toxic effect duration toxic effect drug patient . OUTLINE : Patients receive oral thalidomide daily 2 week twice daily . Treatment continue 1 year absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A maximum 50 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular , papillary , insular , medullary thyroid carcinoma Must meet criterion 1 follow : Unresectable , distantly metastatic tumor concentrate radioactive iodine Follicular papillary thyroid carcinoma large distant tumor burden sufficiently respond cumulative iodine I 131 dos exceed 800 mCi Radiographic evidence tumor progression , meet 1 follow criterion : Evidence gather period least 1 year least 3 separate xray study , define tumor volume Similar radiographic evidence short period time , delineate 30 % increase tumor volume PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 750/mm^3 Hemoglobin least 10.5 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN BUN great 1.5 time ULN Other : No active infection control medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective double contraception ( 1 hormonal method plus 1 barrier method OR 2 simultaneous barrier method ) female patient barrier contraception male patient 4 week prior , , least 4 week study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior thalidomide No concurrent biologic therapy Chemotherapy : At least 4 week since prior systemic chemotherapy No concurrent systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Prior radiotherapy allow Concurrent limit externalbeam radiotherapy isolate site bony metastasis allow , provide site sole site metastatic disease constitute sit evaluable disease study No concurrent radioiodine therapy Surgery : See Disease Characteristics Prior surgery allow Concurrent surgery allow site constitute evaluable disease study Other : No concurrent medication know increase risk peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>insular thyroid cancer</keyword>
</DOC>